April 21, 2022
A look at the unmet needs and future directions of multiple myeloma treatment.
April 21, 2022
Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.
April 19, 2022
Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.
April 19, 2022
An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.
April 19, 2022
A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.
April 19, 2022
A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.
April 04, 2022
A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.
April 04, 2022
Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.
March 25, 2022
A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.
March 25, 2022
An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.